Johnson & Johnson: RYBREVANT combined with chemotherapy achieved the longest reported median overall survival in EGFR exon 20 insertion mutation non-small cell lung cancer.

Johnson & Johnson: RYBREVANT combined with chemotherapy achieved the longest reported median overall survival in EGFR exon 20 insertion mutation non-small cell lung cancer.